18F-FDG PET and CT Response at 3 Months Predict BOR
| Refractory (n = 7) | Responding (n = 9) | |||||
| Parameter | Evaluation | Mean | Median | Mean | Median | P |
| Guideline | ||||||
| ΔSPD-Cheson | BL (cm2) | 23.7 | 20.1 | 40.3 | 16.5 | 0.31 |
| Δ3 | −19% | −17% | −70% | −79% | 0.03 | |
| PET-5PS | 3 mo | 4.43 | 5 | 3.56 | 4 | 0.13 |
| Tumor 18F-FDG uptake | ||||||
| SUVmean | BL | 4.42 | 4.7 | 5.52 | 5.3 | 0.11 |
| Δ3 | −11% | −13% | −54% | −44% | 0.03 | |
| SUVmax | BL | 12.33 | 14.3 | 16.18 | 14.4 | 0.31 |
| Δ3 | −8% | −17% | −63% | −65% | 0.09 | |
| MTV | BL (cm3) | 85 | 54 | 339 | 41 | 0.06 |
| Δ3 | 49% | −37% | −90% | −98% | 0.02 | |
| TLG | BL (SUV⋅cm3) | 85 | 54 | 339 | 41 | 0.06 |
| Δ3 | 49% | −37% | −90% | −98% | 0.02 | |
| Lymphoid 18F-FDG uptake | ||||||
| Spleen | BL* | 3 | 2.9 | 2.67 | 2.5 | 0.46 |
| Δ3* | −14% | −16% | 8% | 5% | 0.03 | |
| Thymus | BL* | 1.62 | 1.5 | 1.76 | 1.9 | 0.6 |
| Δ3* | −5% | 0% | 11% | 8% | 0.6 | |
| Ileocaecal | BL | 3.71 | 2.9 | 2.78 | 2.6 | 0.74 |
| Δ3 | −11% | −7% | 9% | 17% | 0.74 | |
| Osteomedullary | BL† | 2.79 | 2.6 | 3.71 | 3.05 | 0.21 |
| Δ3† | −6% | −13% | −4% | −4% | 0.74 | |
| Sarcopenia | ||||||
| Skeletal muscle index | BL (cm2⋅m-2) | 68 | 65 | 74 | 71 | 0.87 |
| Δ3 | 3% | 3% | 3% | 0% | 1 | |
*Missing data in refractory group.
†Missing data in response group.
Data are distribution of imaging biomarkers in refractory and responding patients at baseline (BL) and changes 3 mo after anti-PD1 initiation (Δ3, expressed as a percentage). Wilcoxon test showed significant differences between the 2 groups.